Premeeting Workshop:
PW6. Hepatitis C Workshop ($)
Wednesday, October 4, 2017: 8:00 AM-12:00 PM
Room: 16AB

Handouts
  • W69- Thomas.pdf (875.3 kB)
  • W70- Marks.pdf (1.4 MB)
  • W71- Wyles.pdf (809.4 kB)
  • W73- Wang.pdf (191.3 kB)
  • W74- Frenette.pdf (981.7 kB)
  • Learning Objectives:

    At the conclusion of this session, participants will be able to:

    • design the treatment options for HCV patients according to their RAVS, treatment experience, HCV genotype, and disease stage
    • compare methods for staging liver disease
    • distinguish steatosis from steatohepatitis
    • diagnose common liver diseases

    Target Audience: Clinicians, HIV clinicians, HIV specialists, Infectious diseases pediatricians, Infectious diseases physicians, Pharmacists

    Tracks: Pediatric ID, HIV-STD-TB, Adult ID


    Pre-Meeting Workshop Moderators:  Eliot Godofsky, MD, FIDSA, Bach and Godofsky and David Thomas, MD, MPH, FIDSA, 7900 Ellenham Ave

    Presentations:
    8:00 AM
    Welcome and Introduction
    8:10 AM
    W69
    Starting Right: Liver Staging
    David Thomas, MD, MPH, FIDSA

    9:00 AM
    W71
    9:30 AM
    W72
    10:10 AM
    Questions
    10:20 AM
    Break
    10:30 AM
    W73
    11:00 AM
    W74
    Hepatology for the ID Doctor
    Catherine Frenette, MD, FAST, AGAF

    11:30 AM
    Questions and Cases

    CME Credits: Maximum of 4.00 hours of AMA PRA Category 1 Credit™

    ACPE Credits: ACPE 4.0 knowledge-based contact hours of pharmacy CE

    ACPE Number: 0221-9999-17-217-L01-P

    Disclosures:

    E. Godofsky, Gilead Pharmaceuticals: Investigator , Research support
    AbbVie: Investigator , Research support
    MSD: Investigator , Research support

    D. Thomas, UpToDate: Editor , Salary
    Oxford University Press: Editor , Salary
    Merck: Scientific Advisor , Consulting fee

    See more of: Premeeting Workshop

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.